About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Two New Drugs for Tuberculosis Developed

by Hannah Joy on October 24, 2017 at 1:08 PM
Font : A-A+

Two New Drugs for Tuberculosis Developed

Two new drugs for tuberculosis treatment have been developed and its ongoing Phase-1 clinical studies have been announced on the eve of the 48th Union World Conference on Lung Health.

The conference is being held in Guadalajara, Mexico, the Global Alliance for TB Drug Development (TB Alliance).

Advertisement


Both compounds have proceeded through early pre-clinical development and were granted "Investigative New Drug" status by the US Food and Drug Administration.

TBA-7371 and Sutezolid are the two new additions to the sparse pipeline of new antibiotics against a disease that not only kills 1.8 million people every year, but is also becoming increasingly resistant to the older drugs.
Advertisement

With resistance to current TB treatments continuously growing, the need for compounds with no pre-existing resistance increases. That is why these two drugs entering human studies give great hope.

TBA-7371 is an antimicrobial compound that belongs to a novel class of drugs known as DprE1 inhibitors, of which there are two other compounds in early development. Its mechanism of action is cell wall disruption.

With no pre-existing resistance or cross-resistance with other TB drugs, TBA-7371 could have significant potential in the treatment of TB. Phase-1 study for this began in August 2017.

Sutezolid, whose phase-1 study started in September 2017, is an oxazolidinone, a class of drugs that has already shown evidence of clinical activity against TB.

The oxazolidinone, linezolid, has shown promising results as part of the Nix-TB study testing a treatment for extensively drug-resistant TB (XDR-TB). However, the toxicity associated with long term administration of linezolid can be problematic.

TB Alliance and the Medicines Patent Pool have already announced a sub licensing agreement for the development and commercialization of sutezolid for the treatment of TB.

It would be pertinent to mention here that two other TB treatment regimens put forward by TB Alliance:

Nix-TB study comprising BPaL regimen (Bedaquiline, Pretomanid, Linezolid and Pyrazinamide) to treat XDR-TB and and N-005 study comprising BPaMZ regimen (Bedaquiline, Pretomanid, Linezolid, Moxifloxacin, Pyrazinamide) to treat drug sensitive as well as drug resistant TB are in advanced stages of clinical studies and have shown very promising results to simplify and improve TB treatment for all forms of TB.

"While we still have a way to go before we arrive at a universal cure for this disease, we have building blocks coming through the research pipeline that show us we can get there," said Dr Mel Spigelman, President and CEO of TB Alliance, in the stakeholders' meeting covered by CNS (Citizen News Service).

The current TB treatment is too lengthy, too toxic and not effective enough in different programmatic settings. Hence there is an urgent need for better drug regimens. But perhaps a harder battle begins after getting a drug approved.

Development plans for uptake of novel regimens must be implemented without avoidable delays and address usage that will have a meaningful impact.



Source: Citizen News Service (CNS)
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Top 7 Benefits of Good Oral Hygiene
Healthy and Safer Thanksgiving 2021
Long-Term Glycemic Control - A Better Measure of COVID-19 Severity
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Tuberculosis Tracheostomy Pleural Effusion Drugs Banned in India Silicosis Screening Tests for Tuberculosis Fever Cough Symptom Evaluation Diet in Tuberculosis 

Recommended Reading
Landmark in Hunt for New TB Drugs Indicated by Trial
Move to find the first new TB combination drug regimen clarified a key hurdle when Phase II ......
India Government to Add More AIDS, TB Drugs to Essential Medicines List
India has about 2.2 million TB patients, the highest in the world, and an estimated 2.1 million are ...
Dip in Stocks of TB Drugs in India, Says WHO
There is a dip in the buffers stock of anti-tuberculosis (TB) drugs in India, says the World Health ...
TB Drugs Preservation and Dosage Record With MIT-Designed Cooler
The novel cooler could facilitate people to encounter antibiotic-resistant tuberculosis....
Cough Symptom Evaluation
Cough is a symptom of a condition usually affecting the respiratory tract. It may be acute or chroni...
Diet in Tuberculosis
Patients with tuberculosis should eat a healthy diet so that they build up their immunity to fight a...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Drugs Banned in India
Several drugs are either banned or withdrawn after introduction in the market....
Fever
Fever or Pyrexia is an elevation in normal body temperature. Causes of fever include infections, inj...
Pleural Effusion
Pleural effusion is the accumulation of fluid in the space between the two coverings (pleura) of the...
Screening Tests for Tuberculosis
Tuberculin skin test and Interferon Release Assays are tests used to screen for tuberculosis....
Silicosis
Silicosis is a lung disease caused by inhalation of crystalline free silica dust. It is characterise...
Tuberculosis
Tuberculosis, caused by Mycobacterium tuberculosis, primarily affects the lung. It may spread to oth...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use